Home › Uveal Melanoma › Arizona › Scottsdale
Uveal Melanoma clinical trials in Scottsdale, AZ
5 studies for Uveal Melanoma are looking for participants at sites in and around Scottsdale (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
RecruitingPhase 3
- Honor Health Research Institute, Scottsdale
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
RecruitingPhase 1/2
- HonorHealth Research Institute, Scottsdale
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Mayo Clinic Scottsdale - PPDS, Scottsdale
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- HonorHealth Research Insisute, Scottsdale
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
RecruitingPhase 1/2
- Honor Health Resarch Institute, Scottsdale
Uveal Melanoma trials in other cities
- Philadelphia, PA7 studies
- Nashville, TN6 studies
- Los Angeles, CA6 studies
- Boston, MA5 studies
- Houston, TX5 studies
- Columbus, OH5 studies
- Denver, CO5 studies
- New York City, NY5 studies
- Aurora, CO4 studies
- Mountain View, CA4 studies
- Pittsburgh, PA4 studies
- Miami, FL4 studies
Other studies in Scottsdale
- Breast Cancer18 studies
- Cancer (all types)18 studies
- Metastatic Cancer17 studies
- Prostate Cancer17 studies
- Colorectal Cancer16 studies
- Non-Small Cell Lung Cancer15 studies
- Pancreatic Cancer13 studies
- Melanoma10 studies
- Ulcerative Colitis8 studies
- Lung Cancer8 studies
- Liver Cancer (Hepatocellular Carcinoma)7 studies
- Alzheimer's Disease7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.